glp 1 drugs and vision loss Wegovy Lawsuit [2026 Update] There’s been a lot of

Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimers and Parkinsons disease therapeutics

Among patients with pre-existing substance use disorder, GLP-1s were tied to fewer hospitalizations, overdoses and deaths related to substance use

Grech, OM James

Retatrutide is setting new records at ~25% or more

Javier Ampudia-Blasco has served as a consultant/advisor for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, LifeScan, MannKind Co., Medtronic, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, LifeScan, Eli Lilly, Madaus, Medtronic, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and has received grant support from Novo Nordisk and Sanofi

Cost may also be a barrier to wide GLP-1RA adoption, according to 93 percent of physicians surveyed